Corporate ActionJul 29, 2026, 04:12 PM
Inhibikase Therapeutics Issues 18M Pre-Funded Warrant
AI Summary
Inhibikase Therapeutics, Inc. announced an exchange agreement with RA Capital Healthcare Fund, L.P. On July 29, 2026, RA Capital exchanged 18,030,000 shares of common stock for a pre-funded warrant to acquire the same number of shares. The warrant has an exercise price of $0.001 per share, is immediately exercisable, and has no expiration date. It includes a beneficial ownership blocker, preventing exercise if it would cause RA Capital's ownership to exceed 9.99% of outstanding shares, though this threshold can be adjusted up to 19.99% with prior notice. The pre-funded warrant was issued without registration in reliance on Section 3(a)(9) of the Securities Act.
Key Highlights
- Inhibikase Therapeutics entered an exchange agreement with RA Capital Healthcare Fund, L.P.
- RA Capital exchanged 18,030,000 common shares for a pre-funded warrant.
- The pre-funded warrant allows acquisition of 18,030,000 common shares.
- Warrant exercise price is $0.001 per underlying share.
- Warrant is immediately exercisable and has no expiration date.
- Includes a beneficial ownership blocker, limiting exercise to 9.99% of outstanding shares.
- Issued without registration under Section 3(a)(9) of the Securities Act.
Price Impact
More from IKT